Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277413 · ClinicalTrials.gov registry record · Phase 1
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
A Phase 1 study of Bladder Cancer and Gastric Adenocarcinoma, sponsored by IDEAYA Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 3
- Study locations
NCT07277413 is a Phase 1 study of Bladder Cancer and Gastric Adenocarcinoma that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 260 participants, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT07277413, a Phase 1 study of Bladder Cancer and Gastric Adenocarcinoma, is actively recruiting participants, sponsored by IDEAYA Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Conditions Studied
Interventions
- DRUG IDE397
- DRUG IDE892
Study Locations (3)
Texas
- NEXT Oncology Houston - Houston
- NEXT Oncology Dallas - Irving
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2026-02-28 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07277413
The ClinicalTrials.gov registry entry for NCT07277413 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The listed sponsor is IDEAYA Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which IDE397 is the first listed.
NCT07277413 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07277413 about?
NCT07277413 is a clinical study titled "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors". This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
What is the current status of trial NCT07277413?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2026-02-28. Estimated completion is 2028-04-30.
What conditions does trial NCT07277413 study?
This clinical trial studies the following conditions: Bladder Cancer, Gastric Adenocarcinoma, Mesothelioma, Peritoneal Mesothelioma, Pleural Mesothelioma.
What interventions are being tested in trial NCT07277413?
The interventions under investigation include: IDE397 (DRUG), IDE892 (DRUG).
Who is sponsoring clinical trial NCT07277413?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07277413 being conducted?
This trial has 3 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.